REG - N4 Pharma PLC - SP Angel Research Note

N4 PharmaAnnouncement

18/11/2020 09:15

RNS Number : 7079F
  
N4 Pharma PLC
  
18 November 2020
  
 

18 November 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
 
SP Angel Research Note
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that its joint broker SP Angel Corporate Finance LLP has issued an initiation research report on the Company.
 
To view SP Angel's research note, please visit the Company's website:
https://www.n4pharma.com/investors/investor-information/
 
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via IFC Advisory




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker


















IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen                                                  


Tel: +44(0)20 3934 6630



 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programmes, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCKVLBFBFLBFBK